LIMN:NASDAQLiminatus Pharma, Inc. Analysis

Liminatus Pharma trades at $0.1798, well below its 20‑day SMA of $0.193 and the 50‑day SMA of $0.396, confirming a bearish price pattern. The RSI of 38 suggests the stock is edging toward oversold territory, while the MACD histogram is marginally positive, indicating a faint bullish signal that has yet to overcome the overall downtrend. Support sits at $0.159 and resistance at $0.245, leaving limited upside in the near term amid a 30‑day volatility of over 84% and a low beta of 0.26, which reduces market‑wide swings but does not mitigate company‑specific risk. Fundamentally, the company reports zero revenue, negative EBITDA of $‑2.97 M, and a negative book value per share, yet its DCF‑derived fair value of $2.13 implies a potential 10‑fold upside if its pre‑clinical CD47 program succeeds. The balance sheet shows modest cash of $0.34 M against $1.44 M of debt, and free cash flow appears positive only due to financing activities, underscoring liquidity concerns. With no dividend, no analyst coverage, and a max drawdown near 100%, the stock is a high‑risk speculative play that hinges on future clinical milestones.